WGS:NASDAQGeneDx Holdings Corp. Analysis
Data as of 2026-09-10 - not real-time
$85.36
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind GeneDx Holdings Corp. is neutral at $85.36, with no clear ordering between short and long averages. The last 30 days have gained 34.0%. With RSI at 58.6 the momentum picture is neutral, alongside a bearish MACD signal. The recent range runs from support at $75.15 up to resistance at $91.78.
Multiples put this in overvalued territory: 73.0 times earnings against the sector's 29.6. The average analyst target implies 6.0% above today's level. Revenue is growing at 11.4% on a -23.4% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 56.2%, a beta of 1.45 and a maximum drawdown of 79.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is sell, conviction 5 out of 10.
Multiples put this in overvalued territory: 73.0 times earnings against the sector's 29.6. The average analyst target implies 6.0% above today's level. Revenue is growing at 11.4% on a -23.4% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 56.2%, a beta of 1.45 and a maximum drawdown of 79.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is sell, conviction 5 out of 10.
Top Market Events
In early August 2026, GeneDx Holdings Corp.Updated Aug 3, 2026 0 NEW YORK-- BUSINESS WIRE --Aug 3, 2026-- Faruqi & Faruqi, LLP, a leading national securities law...WGS Deadline: WGS Investors with Losses in Excess of $100K Have Opportunity to Lead GeneDx Holdings Corp.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 84.13
- MACD momentum is negative
- 30-day price change of +34.0%
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- P/E of 73.0 versus sector average of 29.6
- Trading above the 200-day average of 84.13
- Analyst targets imply +6.0% versus the current price
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- P/E of 73.0 versus sector average of 29.6
- Negative profit margin of -23.4%
- Analyst targets imply +6.0% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth11.40%
Profit Margin-23.41%
P/E Ratio73.0
ROE-40.80%
ROA-7.89%
Debt/Equity68.55
P/B Ratio10.4
Op. Cash Flow$-48712000
Free Cash Flow$-47501624
Industry P/E29.6
Technical Analysis
TrendNeutral
RSI58.6
Support$75.15
Resistance$91.78
MA 20$84.31
MA 50$74.06
MA 200$84.13
MACDBearish
VolumeDecreasing
Fear & Greed Index90.18
Valuation
Target Price$90.44
Upside/Downside5.96%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.45
Volatility56.19%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.